Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Johanna C. Bendell
No relevant relationships to disclose
Thomas J. Ervin
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Donald A. Richards
No relevant relationships to disclose
Irfan Firdaus
No relevant relationships to disclose
A. Craig Lockhart
Research Funding - Keryx
Allen Lee Cohn
No relevant relationships to disclose
Mansoor N. Saleh
Research Funding - Keryx
Lesa R. Gardner
Employment or Leadership Position - Keryx
Stock Ownership - Keryx
Peter Sportelli
Employment or Leadership Position - Keryx
Stock Ownership - Keryx
Cathy Eng
Honoraria - Amgen; Bayer; Genentech
Research Funding - Amgen; Daiichi Sankyo; Keryx